Search
Tetanus immune globulin, human
go.drugbank.com/drugs/DB11604ApprovedInvestigationalTetanus Immune Globulin is manufactured from human plasma [FDA Label]. It contains antibodies against tetanus toxoid and is primarily used as prophylaxis against tetanus in wounded patients.
Products: Hypertet S/d, HyperTET S/D Injection 250 unitsChloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigational[A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387] … [A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a preservative.
Elvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalIt was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.
Valganciclovir
go.drugbank.com/drugs/DB01610ApprovedInvestigationalValganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.
Omega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawn[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia.
Carglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalFood and Drug Administration (FDA) on 18 March 2010. … This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death.
Gadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigational[A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151]
Candesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalUnlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. … Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension.
Mixtures: CORIATROS DUO, Nra-candesartan HctzProducts: Nra-candesartan, CANDESARTAN DOC GENERICIRomosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalRomosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921]. … Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924].
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. … [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.